Mark B. Geyer

IgH class switching and translocations use a robust non-classical end-joining pathway

Catherine T. Yan, Cristian Boboilă, Ellen Kris Souza et al. · Nature · 2007 · 570 citations

Igh Class Switching, Molecular Biology, Systems Biology

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Anthony R. Mato, Lindsey E. Roeker, Nicole Lamanna et al. · Blood · 2020 · 316 citations · Full text

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Alison J. Moskowitz, Paola Ghione, Eric D. Jacobsen et al. · Blood · 2021 · 159 citations · Full text

Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease

Monica Bhatia, Zhezhen Jin, Claire E. Baker et al. · Bone Marrow Transplantation · 2014 · 102 citations

Hematological Malignancy, Translational Medicine, Sickle Cell Disease +6

Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL

Mark B. Geyer, Isabelle Rivière, Brigitte Sénéchal et al. · JCI Insight · 2019 · 98 citations · Full text